MacroGenics (MGNX) Stock Crashes After Reporting Patient Deaths in TAMARACK Study – Hagens Berman
10 mai 2024 18h01 HE
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, May 10, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges MacroGenics, Inc. (NASDAQ: MGNX) investors who suffered substantial losses to submit your losses now. Visit:...
Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 mai 2024 17h38 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, May 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on May 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted...
Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates
10 mai 2024 16h10 HE
|
Entera Bio Ltd.
JERUSALEM, May 10, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today...
AFB Releases Phase 2 Study of Barriers to Digital Inclusion
10 mai 2024 12h39 HE
|
American Foundation for the Blind
AFB Researchers uncover further barriers to digital inclusion for blind and low vision.
Merus gibt Finanzergebnisse für das erste Quartal 2024 bekannt und informiert über den aktuellen Geschäftsverlauf
10 mai 2024 12h36 HE
|
Merus N.V.
Petosemtamab in Kombination mit Pembrolizumab bei 1L (Erstlinientherapie) HNSCC – erste vorläufige klinische Daten auf der ASCO-Jahrestagung 2024; Vorbereitung einer möglichen Phase-III-StudieZeno-BLA...
Merus annonce ses résultats financiers pour le premier trimestre 2024 et fait le point sur ses activités
10 mai 2024 12h36 HE
|
Merus N.V.
Données cliniques intermédiaires initiales concernant le pétosemtamab en association avec le pembrolizumab en traitement de 1re ligne du CETC présentées lors du congrès annuel de l’ASCO 2024 ;...
Anavex Life Sciences Corporation Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before May 13, 2024 to Discuss Your Rights – AVXL
10 mai 2024 12h36 HE
|
Levi & Korsinsky, LLP
NEW YORK, May 10, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Anavex Life Sciences Corporation ("Anavex Life Sciences" or the "Company") (NASDAQ: AVXL) of a class action...
Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation
10 mai 2024 09h35 HE
|
Immix Biopharma, Inc.
92% (12/13) overall response rate (ORR) for relapsed/refractory AL Amyloidosis patients enrolled in NEXICART-1: 12 out of 12 patients not exposed to prior BCMA-targeted bispecific responded to...
Vaccines Market is Expected to Reach $94.9 billion | MarketsandMarkets™
10 mai 2024 08h30 HE
|
MarketsandMarkets Research Pvt. Ltd.
Chicago, May 10, 2024 (GLOBE NEWSWIRE) -- Vaccines market in terms of revenue was estimated to be worth $78.0 billion in 2024 and is poised to reach $94.9 billion by 2029, growing at a CAGR of 4.0%...
iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates
10 mai 2024 08h26 HE
|
iTeos Therapeutics Inc.
- Belrestotug + dostarlimab exceeded pre-defined efficacy criteria for clinically relevant activity observed in an interim assessment of Phase 2 GALAXIES Lung-201- Clinically meaningful tumor...